CHEMBL1889 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Vasopressin V1a receptor shows approved-linked disease relevance led by heart failure. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P37288. Start with heart failure, then reuse UniProt P37288 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with heart failure, then reuse UniProt P37288 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs

Open source guide

Disease program

heart failure

Vasopressin V1a receptor shows approved-linked disease relevance led by heart failure. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with heart failure because it currently carries approved-linked support. Linked drugs include CONIVAPTAN HYDROCHLORIDE, PECAVAPTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Approved-linked Open Targets-ready proxy 2 linked drugs

Open disease block

Protein anchor

Vasopressin V1a receptor

Review this target as Vasopressin V1a receptor, mapped to UniProt P37288. Sequence length is 418 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P37288 Protein 418 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vasopressin V1a receptor as ChEMBL target CHEMBL1889, mapped to UniProt P37288. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Vasopressin V1a receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL1889

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

P37288

Vasopressin V1a receptor

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Vasopressin V1a receptor is the right protein anchor across sources, using UniProt P37288 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why heart failure is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Vasopressin V1a receptor
Target Type	SINGLE PROTEIN
Organism	Homo sapiens
UniProt	P37288

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Vasopressin V1a receptor
UniProt Accession	P37288
Component Type	Protein
Sequence Length	418 aa

Vasopressin V1a receptor

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 15, 2026, 12:06 AM KST As of · Sep 14, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Vasopressin V1a receptor, mapped to UniProt P37288. Sequence length is 418 aa.

Mapped IDP37288

Review nameVasopressin V1a receptor

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Vasopressin V1a receptor shows approved-linked disease relevance led by heart failure. 5 more disease programs remain visible in the same review block.

Approved-linked Approved

heart failure

2 linked drugs · 2 direct · 2 efficacy

Linked drugCONIVAPTAN HYDROCHLORIDE

Linked drugPECAVAPTAN

Late clinical Phase III

autism spectrum disorder

1 linked drug · 1 direct · 1 efficacy

Linked drugBALOVAPTAN

Late clinical Phase III

Hyponatremia

1 linked drug · 1 direct · 1 efficacy

Linked drugCONIVAPTAN HYDROCHLORIDE

Clinical signal Phase II

post-traumatic stress disorder

2 linked drugs · 2 direct · 2 efficacy

Linked drugBALOVAPTAN

Linked drugSRX246

Clinical signal Phase II

Huntington disease

1 linked drug · 1 direct · 1 efficacy

Linked drugSRX246

Clinical signal Phase II

Ischemic stroke

1 linked drug · 1 direct · 1 efficacy

Linked drugBALOVAPTAN

Source · ChEMBL drug mechanism + indication proxy Freshness · Sep 15, 2026, 12:06 AM KST As of · Sep 14, 2026

ChEMBL target record ↗

Review Cue

How to read disease relevance

Start review with heart failure because it currently carries approved-linked support. Linked drugs include CONIVAPTAN HYDROCHLORIDE, PECAVAPTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseheart failure

Strongest levelApproved-linked

Block modeOpen Targets-ready proxy

Clinical Profile

Clinical Phase Distribution

17

Approved

7

Phase III

9

Phase II

2

Phase I

Assay Mix

Activity Type Distribution

IC501,830.0

KI2,148.0

EC50477.0

KD10.0

Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL ID	pChEMBL	Type	Value (nM)	Phase
CHEMBL394602	10.49	Ki	0.032	Preclinical
CHEMBL4094454	10.47	EC50	0.034	Preclinical
CHEMBL1807272	10.43	Ki	0.03715	Preclinical
CHEMBL1807267	10.4	Ki	0.03981	Preclinical
CHEMBL1083094	10.3	Ki	0.05	Preclinical
CHEMBL1084823	10.22	Ki	0.06	Preclinical
CHEMBL6027125	10.2	Ki	0.063	Preclinical
CHEMBL540192	10.15	Ki	0.07	Preclinical
CHEMBL269012	10.1	Ki	0.08	Preclinical
CHEMBL1161978	10.05	Ki	0.09	Preclinical

Distribution

pChEMBL Value Distribution

102

5.0

137

5.5

186

6.0

225

6.5

273

7.0

296

7.5

298

8.0

238

8.5

191

9.0

72

9.5

pChEMBL

Approved Drugs

VASOPRESSIN

CHEMBL373742

Approved 2014

Properties Compare Identifier

TOLVAPTAN

CHEMBL344159

Approved 2009

Properties Compare Identifier

MOZAVAPTAN

CHEMBL420762

Approved 2006

Properties Compare Identifier

CONIVAPTAN

CHEMBL1755

Approved 2005

Properties Compare Identifier

ATOSIBAN

CHEMBL382301

Approved 2000

Properties Compare Identifier

OXYTOCIN

CHEMBL395429

Approved 1980

Properties Compare Identifier

DESMOPRESSIN

CHEMBL1429

Approved 1978

Properties Compare Identifier

Assay Landscape

414

Total Assays

1,350

Tested Compounds

3

Assay Types

Binding — 301 assays, 1,350 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
single protein format	179	274	7.8
cell-based format	98	674	7.3
assay format	18	382	7.7
cell membrane format	6	20	7.3

Functional — 105 assays, 411 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
cell-based format	87	383	7.5
assay format	18	28	6.4

ADME — 8 assays, 27 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
cell-based format	8	27	8.4

CHEMBL1889 Target Snapshot

Research home keeps recent targets

Switch target

Frame the target before identity details

Cross-source identity

Start with the right source

Basic Information

Next Actions

UniProt Target Context

How to read this target

Disease Relevance & Evidence Level

How to read disease relevance

Clinical Phase Distribution

Activity Type Distribution

Top Inhibitors (by pChEMBL)

pChEMBL Value Distribution

Approved Drugs

Assay Landscape

Confidence Score Distribution